Michael Geffner

Michael Geffner, MD, MBA

Michael Geffner, MD, MBA, joins BlueSphere Bio from Achillion Pharmaceuticals (now a wholly-owned subsidiary of Alexion Pharmaceuticals), where he was Senior Vice President and led the hematology clinical development efforts for the company as well as global medical affairs for all Achillion programs. Dr Geffner designed, implemented and managed all global hematology clinical trials in paroxysmal nocturnal hemoglobinuria with the company’s lead asset, danicopan (an oral, small molecule factor D inhibitor of the complement system’s alternative pathway). Prior to Achillion, Dr Geffner spent 15 years in various positions of increasing responsibility at Schering-Plough and Merck, including Clinical Development, Clinical Operations and Medical Affairs. 

In his most recent role prior to Achillion, he was the US head of the anti-infectives, hospital/specialty care and anesthesia medical affairs teams for Merck. In this role, he led the HIV, HCV, antibiotic, antifungal and anesthesia/surgical portfolios, and also served as the medical affairs integration lead for the acquisition of Cubist Pharmaceuticals.

At Schering Plough, Dr Geffner was a key leader of the Peg-Intron NDA team and also designed and conducted the first Phase 2 clinical trial for Boceprevir at Schering-Plough. He made significant contributions to the integration process when Schering Plough acquired Organon Biosciences, and integrated their portfolio and team into his clinical operations team. The structure launched by Dr Geffner in North America was then adapted and launched worldwide at Schering Plough and he assisted in rolling out this structure around the globe. He also led clinical operations for Europe II, Middle East and Africa, which contained approximately 70 countries. He continued in an operations capacity when Schering-Plough was acquired by Merck and led clinical operations for North America at Merck and had a team that covered all phases of research, with well over 100 clinical trials in the portfolio and a team size that exceeded 400 individuals.

Dr Geffner is a US licensed physician with dual board certification from the American Board of Pediatrics and the American Board of Psychiatry and Neurology, with special competency in Child Neurology. He is a graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University.